Beclometasone intravitreal

Drug Profile

Beclometasone intravitreal

Alternative Names: AGN 208 397; Beclometasone intravitreous

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Allergan
  • Class Antiallergics; Antiasthmatics; Chlorinated steroids; Corticosteroids; Pregnadienetriols; Small molecules; Vascular disorder therapies
  • Mechanism of Action Immunosuppressants; Steroid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Retinal disorders
  • No development reported Retinal oedema

Most Recent Events

  • 17 Sep 2015 No recent reports on development identified - Phase-I/II for Retinal oedema in USA, Canada, Australia, South Africa and Israel (Intravitreous)
  • 01 Feb 2013 Allergan completes phase I/II trial in Retinal oedema in USA, Canada, Australia, Israel and South Africa (NCT01027650)
  • 01 Mar 2010 Phase-I/II clinical trials in Retinal oedema in Canada (Intravitreous)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top